How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/subependymal-giant-cell-astrocytoma-associated-with-tuberous-sclerosis.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-11 · How we verify

Subependymal Giant Cell Astrocytoma associated with Tuberous Sclerosis — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Subependymal Giant Cell Astrocytoma associated with Tuberous Sclerosis (disease) competitive landscape: 2 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

2 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Subependymal Giant Cell Astrocytoma associated with Tuberous Sclerosis, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	Line of therapy	First approval
Afinitor	everolimus	Novartis	Kinase Inhibitor [EPC]	Serine/threonine-protein kinase mTOR		2009-01-01
Afinitor	Afinitor	Central European Society for Anticancer Drug Research		Multidrug resistance protein 1, Peptidyl-prolyl cis-trans isomerase FKBP1A, Serine/threonine-protein kinase mTOR

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Central European Society for Anticancer Drug Research · 1 drug in Subependymal Giant Cell Astrocytoma associated with Tuberous Sclerosis
Novartis · 1 drug in Subependymal Giant Cell Astrocytoma associated with Tuberous Sclerosis

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Subependymal Giant Cell Astrocytoma associated with Tuberous Sclerosis:

Cite this brief

Drug Landscape (2026). Subependymal Giant Cell Astrocytoma associated with Tuberous Sclerosis — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/subependymal-giant-cell-astrocytoma-associated-with-tuberous-sclerosis. Accessed 2026-06-11.

Subependymal Giant Cell Astrocytoma associated with Tuberous Sclerosis full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing